Literature DB >> 16996272

Hyperimmune goat serum for amyotrophic lateral sclerosis.

R Mackenzie1, M Kiernan, D McKenzie, B D Youl.   

Abstract

The authors report a patient with amyotrophic lateral sclerosis (ALS) who showed a lessening of deterioration in respiratory muscle strength during treatment with hyperimmune goat serum (HGS) (Aimspro). Respiratory function tests (RFTs) were measured by established protocols, and all measurements were expressed as a percentage of normal predicted values. The rate of decline was calculated by linear regression analysis. Respiratory muscle strength decline was less during 13 months of treatment with HGS (mean 1.3% per month, range 0.8-1.7%) compared to the preceding 13 months (mean 2.3% per month, range 1.2-3.1%), while a greater decline would be expected with disease progression. Comparison with similarly affected patients in the literature suggest that a decline of 4-5% per month of predicted values may be expected during the treatment phase.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16996272     DOI: 10.1016/j.jocn.2006.03.009

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  2 in total

1.  The preclinical discovery of amyotrophic lateral sclerosis drugs.

Authors:  Marcie A Glicksman
Journal:  Expert Opin Drug Discov       Date:  2011-10-25       Impact factor: 6.098

2.  Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum in systemic sclerosis.

Authors:  Niamh Quillinan; Kristina E N Clark; Bryan Youl; Jeffrey Vernes; Deirdre McIntosh; Syed Haq; Christopher P Denton
Journal:  Arthritis Res Ther       Date:  2017-03-07       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.